Inflammatory Signaling Compromises Cell Responses to Interferon Alpha

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2011 Jun 14

PMID 21666722

Citations 49

Authors

W-C HuangFu

J Qian

C Liu

J Liu

A E Lokshin

D P Baker

H Rui

S Y Fuchs

Affiliations

Soon will be listed here.

Abstract

Interferon alpha (IFNα) is widely used for treatment of melanoma and certain other malignancies. This cytokine as well as the related IFNβ exerts potent anti-tumorigenic effects; however, their efficacy in patients is often suboptimal. Here, we report that inflammatory signaling impedes the effects of IFNα/β. Melanoma cells can secrete pro-inflammatory cytokines that inhibit cellular responses to IFNα/β via activating the ligand-independent pathway for the phosphorylation and subsequent ubiquitination and accelerated degradation of the IFNAR1 chain of type I IFN receptor. Catalytic activity of the p38 protein kinase was required for IFNAR1 downregulation and inhibition of IFNα/β signaling induced by proinflammatory cytokines such as interleukin 1 (IL-1). Activation of p38 kinase inversely correlated with protein levels of IFNAR1 in clinical melanoma specimens. Inhibition of p38 kinase augmented the inhibitory effects of IFNα/β on cell viability and growth in vitro and in vivo. The roles of inflammation and p38 protein kinase in regulating cellular responses to IFNα/β in normal and tumor cells are discussed.

Citing Articles

TNF-α-induced down-regulation of type I interferon receptor contributes to acquired resistance of cervical squamous cancer to Cisplatin.

Yu Y, Yu J, Cui X, Sun X, Yu X J Antibiot (Tokyo). 2023; 77(2):102-110.

PMID: 38102186 DOI: 10.1038/s41429-023-00686-z.

[Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].

Luo D, Luo J, Liang H, He Z, Chen H, Wen Z Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(6):1029-1034.

PMID: 37439177 PMC: 10339308. DOI: 10.12122/j.issn.1673-4254.2023.06.20.

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma.

Chaudhary R, Slebos R, Noel L, Song F, Poole M, Hoening D Cancer Res Commun. 2023; 3(5):896-907.

PMID: 37377902 PMC: 10202124. DOI: 10.1158/2767-9764.CRC-22-0443.

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.

Hasselbalch H, Skov V, Kjaer L, Larsen M, Knudsen T, Lucijanic M Cancers (Basel). 2022; 14(22).

PMID: 36428587 PMC: 9688061. DOI: 10.3390/cancers14225495.

Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells.

McBrearty N, Cho C, Chen J, Zahedi F, Peck A, Radaelli E Mol Cancer Res. 2022; 21(3):228-239.

PMID: 36378658 PMC: 9992122. DOI: 10.1158/1541-7786.MCR-22-0602.

References

Rigual N, Popat S, Jayaprakash V, Jaggernauth W, Wong M . Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther. 2008; 8(3):403-12. DOI: 10.1586/14737140.8.3.403. View

Weber A, Wasiliew P, Kracht M . Interleukin-1 (IL-1) pathway. Sci Signal. 2010; 3(105):cm1. DOI: 10.1126/scisignal.3105cm1. View

Goldman L, Zafari M, Cutrone E, Dang A, Brickelmeier M, Runkel L . Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res. 1999; 19(1):15-26. DOI: 10.1089/107999099314379. View

Nazarian R, Prieto V, Elder D, Duncan L . Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010; 37 Suppl 1:41-7. DOI: 10.1111/j.1600-0560.2010.01505.x. View

Messina J, Yu H, Riker A, Munster P, Jove R, Daud A . Activated stat-3 in melanoma. Cancer Control. 2008; 15(3):196-201. DOI: 10.1177/107327480801500302. View

Soengas M, Lowe S . Apoptosis and melanoma chemoresistance. Oncogene. 2003; 22(20):3138-51. DOI: 10.1038/sj.onc.1206454. View

Linkov F, Ferris R, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Gooding W . Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl. 2009; 2(12):1575-1585. PMC: 2645643. DOI: 10.1002/prca.200780095. View

Bregman H, Carroll P, Meggers E . Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc. 2006; 128(3):877-84. DOI: 10.1021/ja055523r. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

10.

Uze G, Schreiber G, Piehler J, Pellegrini S . The receptor of the type I interferon family. Curr Top Microbiol Immunol. 2007; 316:71-95. DOI: 10.1007/978-3-540-71329-6_5. View

11.

Yurkovetsky Z, Kirkwood J, Edington H, Marrangoni A, Velikokhatnaya L, Winans M . Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007; 13(8):2422-8. DOI: 10.1158/1078-0432.CCR-06-1805. View

12.

Roux P, Blenis J . ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004; 68(2):320-44. PMC: 419926. DOI: 10.1128/MMBR.68.2.320-344.2004. View

13.

Bhattacharya S, HuangFu W, Liu J, Veeranki S, Baker D, Koumenis C . Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem. 2009; 285(4):2318-25. PMC: 2807289. DOI: 10.1074/jbc.M109.071498. View

14.

Liu J, Kumar K, Yu D, Molton S, McMahon M, Herlyn M . Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2006; 26(13):1954-8. PMC: 1903341. DOI: 10.1038/sj.onc.1209994. View

15.

Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris D . Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2009; 285(9):6477-88. PMC: 2825443. DOI: 10.1074/jbc.M109.064907. View

16.

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

17.

Bracarda S, Eggermont A, Samuelsson J . Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer. 2009; 46(2):284-97. DOI: 10.1016/j.ejca.2009.10.013. View

18.

Germano G, Allavena P, Mantovani A . Cytokines as a key component of cancer-related inflammation. Cytokine. 2008; 43(3):374-9. DOI: 10.1016/j.cyto.2008.07.014. View

19.

Kock A, Schwarz T, Urbanski A, Peng Z, Vetterlein M, Micksche M . Expression and release of interleukin-1 by different human melanoma cell lines. J Natl Cancer Inst. 1989; 81(1):36-42. DOI: 10.1093/jnci/81.1.36. View

20.

Kaehler K, Sondak V, Schadendorf D, Hauschild A . Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer. 2009; 46(1):41-6. DOI: 10.1016/j.ejca.2009.10.004. View